Home

Terumo Corp (TRUMF)

19.94
+2.10 (11.76%)
OP · Last Trade: Jun 10th, 9:39 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Arterial Device-Focused Inari Medical Likely Acquisition Target, Shares Are Attractively Valued: Analystbenzinga.com
Inari Medical with strong position in venous thrombectomy. Buy-rated by Needham with a $72 target. Undervalued shares with an 88% gross margin and anticipated double-digit revenue growth.
Via Benzinga · January 23, 2024